ACADIA Announces Results from Phase III Trial of Pimavanserin in Parkinson’s Disease Psychosis

News   Sep 02, 2009

 
ACADIA Announces Results from Phase III Trial of Pimavanserin in Parkinson’s Disease Psychosis
 
 
 

RELATED ARTICLES

First-in-Human Trial Evaluating Ebola Treatment Begins

News

A first-in-human trial evaluating an experimental treatment for Ebola virus disease has begun. The Phase 1 clinical trial is examining the safety and tolerability of a single monoclonal antibody called mAb114

READ MORE

Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT Biotech

News

Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.

READ MORE

New Chemistry to Make Smart Drugs Smarter

News

A method to activate targeted drugs, or smart drugs, only at the selected site of action, an approach that improves the drug’s therapeutic effect and minimizes side effects, has been developed in a study led by Georgia State University.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE